SEC Comment Letter 0000000000-24-011951 to OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715) (OKUR)
OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715)
Date: Oct. 25, 2024 · CIK: 0001637715 · Accession: 0000000000-24-011951
AI Filing Summary & Sentiment
File numbers found in text: 333-282792
Letter
October 25, 2024 Nicholas Saccomano Chief Executive Officer OnKure Therapeutics, Inc. 6707 Winchester Circle, #400 Boulder, CO 80301 Re:OnKure Therapeutics, Inc. Registration Statement on Form S-1 Filed October 23, 2024 File No. 333-282792 Dear Nicholas Saccomano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jennifer Knapp, Esq.
Show Raw Text
October 25, 2024
Nicholas Saccomano
Chief Executive Officer
OnKure Therapeutics, Inc.
6707 Winchester Circle, #400
Boulder, CO 80301
Re:OnKure Therapeutics, Inc.
Registration Statement on Form S-1
Filed October 23, 2024
File No. 333-282792
Dear Nicholas Saccomano:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jennifer Knapp, Esq.